Plate K H, Mennel H D
Department of Neuropathology, Philipps-University Marburg, Germany.
Exp Toxicol Pathol. 1995 May;47(2-3):89-94. doi: 10.1016/S0940-2993(11)80292-7.
Intracranial tumor classification is paralleled by a grading system that empirically compares tumor entities with "progression stages" of supratentorial gliomas of the adult. This grading system is an integral part of the WHO classification. Glioma progression has originally been defined by descriptive morphology. In this respect, morphological key features of high-grade gliomas (WHO grades III and IV) are microvascular proliferation and the formation of tumor necroses. Glioma progression is now more accurately defined on the molecular genetic level by a stepwise accumulation of oncogene activation and/or tumor suppressor gene inactivation. Angiogenesis occurs during development and progression of glial tumors. Pathological vessels are a hallmark of malignant glioma and it has therefore been suggested that malignant glioma cells are able to induce neovascularization. Despite the exuberant neovascularisation, however, vascular supply may not be sufficient for tumor areas with high cell proliferation, and necroses may develop. Malignant transformation of blood vessel itself is a rare event but may be the underlying mechanism of gliosarcoma development. The recently purified vascular endothelial growth factor (VEGF) is at present the only mitogen known to selectively act on endothelial cells. Growing evidence suggests that VEGF is the key regulator of developmental and pathological angiogenesis. In vivo, VEGF mRNA is upregulated in a subpopulation of malignant glioma cells adjacent to necroses. Since VEGF is hypoxia-inducible, hypoxia may be an important regulator of VEGF mRNA expression and tumor angiogenesis in vivo. Two tyrosine kinase receptors for VEGF are expressed in vessels which invade the tumor, suggesting that tumor angiogenesis is regulated by a paracrine mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)
颅内肿瘤的分类与一个分级系统相对应,该系统根据经验将肿瘤实体与成人幕上神经胶质瘤的“进展阶段”进行比较。这个分级系统是世界卫生组织分类的一个组成部分。神经胶质瘤的进展最初是通过描述性形态学来定义的。在这方面,高级别神经胶质瘤(世界卫生组织III级和IV级)的形态学关键特征是微血管增殖和肿瘤坏死的形成。现在,神经胶质瘤的进展在分子遗传学水平上通过癌基因激活和/或肿瘤抑制基因失活的逐步积累得到更准确的定义。血管生成发生在胶质肿瘤的发生和发展过程中。病理性血管是恶性神经胶质瘤的一个标志,因此有人提出恶性神经胶质瘤细胞能够诱导新血管形成。然而,尽管有旺盛的新血管生成,但对于细胞增殖高的肿瘤区域,血管供应可能不足,坏死可能会发生。血管本身的恶性转化是一种罕见事件,但可能是胶质肉瘤发生的潜在机制。最近纯化的血管内皮生长因子(VEGF)是目前已知的唯一选择性作用于内皮细胞的促有丝分裂原。越来越多的证据表明,VEGF是发育性和病理性血管生成的关键调节因子。在体内,VEGF mRNA在与坏死灶相邻的恶性神经胶质瘤细胞亚群中上调。由于VEGF是缺氧诱导的,缺氧可能是体内VEGF mRNA表达和肿瘤血管生成的重要调节因子。两种VEGF酪氨酸激酶受体在侵入肿瘤的血管中表达,这表明肿瘤血管生成是由旁分泌机制调节的。(摘要截短于250字)